Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103


Crizotinib-induced immunogenic cell death in non-small cell lung cancer.

Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, Martin T, Xia L, Yang H, Li Q, Chen J, Durand S, Aprahamian F, Lefevre D, Broutin S, Paci A, Bongers A, Minard-Colin V, Tartour E, Zitvogel L, Apetoh L, Ma Y, Pittet MJ, Kepp O, Kroemer G.

Nat Commun. 2019 Apr 2;10(1):1486. doi: 10.1038/s41467-019-09415-3. Erratum in: Nat Commun. 2019 Apr 17;10(1):1883.


Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.

Herzberg B, Campo MJ, Gainor JF.

Oncologist. 2017 Jan;22(1):81-88. doi: 10.1634/theoncologist.2016-0189. Epub 2016 Aug 17. Review.


Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.

Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, Zhang Y, He X, Zhou T, Qin T, Huang Y, Yi X, Zhang L.

J Thorac Oncol. 2015 Jun;10(6):910-23. doi: 10.1097/JTO.0000000000000500.


Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.

Sui H, Ma N, Wang Y, Li H, Liu X, Su Y, Yang J.

J Immunol Res. 2018 Aug 8;2018:6984948. doi: 10.1155/2018/6984948. eCollection 2018. Review.


PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?

Tanvetyanon T, Gray JE, Antonia SJ.

Expert Opin Biol Ther. 2017 Mar;17(3):305-312. doi: 10.1080/14712598.2017.1280454. Epub 2017 Jan 18. Review.


The next generation of immunotherapy: keeping lung cancer in check.

Somasundaram A, Burns TF.

J Hematol Oncol. 2017 Apr 24;10(1):87. doi: 10.1186/s13045-017-0456-5. Review.


Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M, Giles FJ.

Clin Lung Cancer. 2016 Sep;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011. Epub 2016 Apr 6. Review.


Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.

Rojkó L, Reiniger L, Téglási V, Fábián K, Pipek O, Vágvölgyi A, Agócs L, Fillinger J, Kajdácsi Z, Tímár J, Döme B, Szállási Z, Moldvay J.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1219-1226. doi: 10.1007/s00432-018-2642-4. Epub 2018 Apr 19.


Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.

Takamori S, Toyokawa G, Takada K, Shoji F, Okamoto T, Maehara Y.

Clin Lung Cancer. 2018 Jan;19(1):12-16. doi: 10.1016/j.cllc.2017.06.015. Epub 2017 Jul 6. Review.


PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.

Kluger HM, Zito CR, Turcu G, Baine MK, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB.

Clin Cancer Res. 2017 Aug 1;23(15):4270-4279. doi: 10.1158/1078-0432.CCR-16-3146. Epub 2017 Feb 21.


Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.

Chow LQ.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e280. Review.


Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.

Funaki S, Shintani Y, Kawamura T, Kanzaki R, Minami M, Okumura M.

Oncol Rep. 2017 Oct;38(4):2277-2284. doi: 10.3892/or.2017.5894. Epub 2017 Aug 9.


Crizotinib - a tyrosine kinase inhibitor that stimulates immunogenic cell death.

Liu P, Zhao L, Kepp O, Kroemer G.

Oncoimmunology. 2019 Apr 13;8(7):1596652. doi: 10.1080/2162402X.2019.1596652. eCollection 2019.


Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).

Spigel DR, Reynolds C, Waterhouse D, Garon EB, Chandler J, Babu S, Thurmes P, Spira A, Jotte R, Zhu J, Lin WH, Blumenschein G Jr.

J Thorac Oncol. 2018 May;13(5):682-688. doi: 10.1016/j.jtho.2018.02.022. Epub 2018 Mar 6.


Atezolizumab for the treatment of non-small cell lung cancer.

Santini FC, Rudin CM.

Expert Rev Clin Pharmacol. 2017 Sep;10(9):935-945. doi: 10.1080/17512433.2017.1356717. Epub 2017 Jul 27. Review.


Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.

Soo RA, Lim SM, Syn NL, Teng R, Soong R, Mok TSK, Cho BC.

Lung Cancer. 2018 Jan;115:12-20. doi: 10.1016/j.lungcan.2017.11.009. Epub 2017 Nov 13. Review.


Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration.

Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM.

Clin Cancer Res. 2017 Aug 15;23(16):4556-4568. doi: 10.1158/1078-0432.CCR-16-2821. Epub 2017 May 3.


New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1.

Villanueva N, Bazhenova L.

Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618794133. doi: 10.1177/1753466618794133. Review.


Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.

El-Guindy DM, Helal DS, Sabry NM, Abo El-Nasr M.

J Egypt Natl Canc Inst. 2018 Dec;30(4):125-131. doi: 10.1016/j.jnci.2018.08.003. Epub 2018 Oct 15.


Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?

Qiao M, Jiang T, Ren S, Zhou C.

Clin Lung Cancer. 2018 Jan;19(1):1-11. doi: 10.1016/j.cllc.2017.06.005. Epub 2017 Jun 23. Review.


Supplemental Content

Support Center